Watson filed Sanctura XR PIV

Per Watson press release. Not a big pr0duct, but apparently good enough for Watson.

King to refile Remoxy NDA in 2010

Based on press release today, what is missing is 6-month stability data, rather than new clinical trials.

Mylan and Biocon

Teamed up for bio-generics.

Hospira Receives Favorable Court Decision on Eloxatin

-- Has Tentative FDA Approval and Expects Final Approval Shortly --

LAKE FOREST, Ill., June 18 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP) , the world leader in generic injectable pharmaceuticals, today announced that the U.S. District Court for the District of New Jersey has granted summary judgment of non-infringement in Hospira's favor with regard to Sanofi Aventis' chemotherapy medicationEloxatin (R), and that Hospira has tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of the product. Hospira expects full FDA approval shortly.

Generic advances

Teva got generic Yaz approved. Concerta patents knocked out.

Developments on the generic front

1. Teva and Medicis settled Solodyn case after Teva's at-risk launch. Teva ceased shipping, was relived by Medicis from any claim, but would launch again in 2011 or earlier, under certain circumstances.

2. Impax started co-promoting Pristiq as part of the Effexor XR settlement.

Biologics

Roche finally secured the Genentech deal.

In the mean time, generic biologic legislation has regained momentum.